Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women

European Journal of Cancer

Volumn 35, Issue 4, 1999, Pages 596-600

  Decensi, A ^a   Robertson, C ^a   Ballardini, B ^a   Paggi, D ^b   Guerrieri Gonzaga, A ^a   Bonanni, B ^a   Manetti, L ^a   Johansson, H ^c   Barreca, A ^c   Bettega, D ^d   Costa, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Angelo Bianchi Bonomi Hemophilia and Thrombosis Center   (Italy)

Author keywords

Breast cancer; Chemoprevention; Lipoprotein(a); Somatomedins; Tamoxifen

Indexed keywords

BIOLOGICAL MARKER; LIPOPROTEIN A; PLACEBO; SOMATOMEDIN C; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN EXPERIMENT; ISCHEMIC HEART DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; BREAST NEOPLASMS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPOPROTEIN(A); MIDDLE AGED; TAMOXIFEN;

EID: 0033119846     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00428-6     Document Type: Article

References (22)

1. Early Breast Cancer Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1991, 351, 1451-1467.
2. Fisher B., Costantino J.P., Wickerman D.L., et al. Tamoxifen for prevention of breast cancer: report of the national Surgical Adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. 90:1998;1371-1388.
3. Veronesi U., Maisonneuve P., Costa A., et al. on behalf of the Italian Tamoxifen Prevention Study. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet. 352:1998;93-97.
4. Powles T., Eeeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 352:1998;98-101.
5. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease (see comments). Arch. Intern. Med. 1997, 157, 1170-1176; 1161-1162.
6. Bostom A.G., Gagnon D.R., Cupples L.A., et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation. 90:1994;1688-1695.
7. Schaefer E.J., Lamon-Fava S., Jenner J.L., et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 271:1994;999-1003.
8. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger (see comments). A prospective study. JAMA 1996, 276, 544-548; JAMA 1997, 277, 209-210.
9. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger (see comments). A prospective study. JAMA 1996, 276, 544-548; JAMA 1997, 277, 209-210.
10. Orth-Gomer K., Mittleman M.A., Schenck-Gustafsson K., et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 95:1997;329-334.
11. Love R.R., Wiebe D.A., Feyzi J.M., Newcomb P.A., Chappell R.J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 86:1994;1534-1539.
12. Shewmon D.A., Stock J.L., Rosen C.J., et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 14:1994;1586-1593.
13. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393-1396.
14. Levine D.M., Sloan B.J., Donner J.E., Lorenz J.D., Heinzerling R.H. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int. J. Clin. Lab. Res. 22:1992;173-178.
15. Decensi A., Robertson C., Rotmensz N., et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a breast cancer prevention trial. Br. J. Cancer. 78:1998;572-578.
16. Decensi A., Bonanni B., Guerrieri-Gonzaga A., et al. Biological activity of tamoxifen at low doses in healthy women. J. Natl. Cancer Inst. 90:1998;1461-1467.
17. Zysow B.R., Kauser K., Lawn R.M., Rubanyi G.M. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 17:1997;1741-1745.
18. Laron Z., Wang X.L., Klinger B., Silbergeld A., Wilcken D.E. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism. 45:1996;1263-1266.
19. Zmunda J.M., Thompson P.D., Dickenson R., Bausserman L.L. Testosterone decreases lipoprotein(a) in men. Am. J. Cardiol. 77:1996;1244-1247.
20. Olivecrona H., Johansson A.G., Lindh E., Ljunghall S., Berglund L., Angelin B. Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I. Arterioscler. Thromb. Vasc. Biol. 15:1995;847-849.
21. Duell P.B., Hagemenas F., Connor W.E. The relationship between serum lipoprotein(a) and insulinemia in healthy nondiabetic adult men. Diabetes Care. 17:1994;1135-1140.
22. Grainger D.J., Witchell C.M., Metcalfe J.C. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat. Med. 1:1995;1067-1073.